Pull to refresh
Logo
Lecanemab slows decline in Alzheimer's patients who also carry Lewy-body protein

Lecanemab slows decline in Alzheimer's patients who also carry Lewy-body protein

New Capabilities

An exploratory 82-patient slice of the Clarity AD trial found 41% slowing in α-synuclein carriers, against 27% for the trial overall

Overview

Updated 19 minutes ago

Eisai and Biogen screened 623 spinal fluid samples from the Clarity AD trial for α-synuclein, the protein that clumps into Lewy bodies in Parkinson's disease and dementia with Lewy bodies. Twenty percent of the amyloid-positive volunteers carried it, twice the rate of the amyloid-negative group. Among the 82 carriers who received lecanemab, decline on the CDR-SB dementia scale ran 41% slower than placebo, against 27% across the whole trial.

The result loosens a suspected limit on who the drug helps. It does not show a bigger benefit. The analysis was exploratory and run after the trial ended, the companies reported no confidence intervals, no absolute point differences and no subgroup safety data, and the work was presented at a conference rather than published.

α-synuclein co-pathology is common in Alzheimer's and is tied to faster decline and to hallucinations and movement symptoms. Before seed amplification assays, it could only be confirmed at autopsy. The SYNTap test used here multiplies misfolded protein from a spinal fluid sample until it becomes detectable, which is what made the subgroup countable at all.

Why it matters

About one in five amyloid-positive Alzheimer's patients also carries α-synuclein clumps; this analysis suggests that co-pathology does not blunt lecanemab's benefit.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

41%
Slowing of decline in α-synuclein-positive patients
Reduction in CDR-SB decline versus placebo among the 82 carriers, an exploratory post hoc figure.
27%
Slowing of decline across all of Clarity AD
The overall trial result on CDR-SB at 18 months, reported in 2022.
20.4%
α-synuclein prevalence in amyloid-positive samples
Against 10.0% in amyloid-negative samples, a difference the companies call statistically significant.
82
Patients in the α-synuclein-positive subgroup
Drawn from 400 randomized participants who had a valid test result.
623
Spinal fluid samples screened
Collected at screening or baseline from Clarity AD volunteers.
1,795
Total Clarity AD enrollment
The randomized, placebo-controlled population the subgroup was carved from.
86 CL
Baseline amyloid burden in carriers
Measured in Centiloids on PET imaging; non-carriers averaged 67 CL, and the trial mean was about 78 CL.

Voices

Curated perspectives — historical figures and your fellow readers.

Sign up to generate historical perspectives on this story.

Organizations Involved

Timeline

September 2022 November 2026

6 events Latest: 3 days ago
Tap a bar to jump to that date
  1. CSF substudy presented at CTAD

    Latest Conference

    Carriers of α-synuclein seeds show 41% slowing versus 27% trial-wide.

  2. Cochrane review lands

    Analysis

    Review of 17 anti-amyloid trials finds no clinically meaningful benefit.

  3. Traditional approval granted

    Regulatory

    FDA converts lecanemab to full approval for early Alzheimer's disease.

  4. Accelerated approval granted

    Regulatory

    FDA clears lecanemab on the basis of amyloid plaque reduction.

  5. Full trial results published

    Publication

    The 1,795-patient Clarity AD results appear in the New England Journal of Medicine.

  6. Clarity AD topline announced

    Trial

    Eisai and Biogen report 27% slowing on CDR-SB over 18 months.

Scenarios

1

Peer review publishes the α-synuclein subgroup result

Likely Resolves by Nov 19, 2027

Discussed by: The companies, which called the analysis exploratory and presented it without peer review; no independent analyst commentary has appeared yet

A journal version would show the confidence intervals and point estimates the conference abstract left out. If the effect shrinks toward the trial-wide 27%, the co-pathology story fades. If it holds near 41% in 82 patients, the result becomes a fixed reference for anyone designing the next trial.

2

Eisai and Biogen register a trial that selects on α-synuclein status

Possible Resolves by End of 2027

Discussed by: Researchers quoted in coverage of the presentation, who raised whether co-pathology should shape who receives anti-amyloid treatment

A prospective study with α-synuclein status as an entry criterion or a stratification factor would turn a post hoc observation into a testable question. That is the step that separates a conference finding from a change in how trials are built.

3

Regulators require α-synuclein testing before lecanemab

Unlikely Resolves by End of 2028

Discussed by: Patient guidance published alongside the data, which states explicitly that patients should not be tested for α-synuclein before treatment

The approved label covers early Alzheimer's with confirmed amyloid, and the new data have not changed eligibility. A testing requirement would need regulators to treat co-pathology as a gate rather than a descriptor. Nothing in the presentation points that way.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

June 2021 - January 2024

Aducanumab approval and withdrawal (2021-2024)

The FDA approved aducanumab on June 7, 2021, the first drug cleared for removing amyloid plaques from the brain. The agency's own advisory committee had voted against it, and two large trials had been stopped for futility before a post hoc analysis found benefit at a high dose. Medicare then limited coverage to patients enrolled in clinical trials.

Then

Few patients received the drug, and Biogen halved the price.

Now

Biogen discontinued aducanumab and shifted its Alzheimer's effort to lecanemab.

Why this matters now

It set the evidentiary bar the class still works against: clearing plaques is not enough unless a clinical benefit survives scrutiny.

2003-2015

Gefitinib and the EGFR subgroup (2003-2015)

Gefitinib won accelerated US approval for lung cancer in 2003. A confirmatory trial then failed to show a survival benefit across all patients, and the label was narrowed in 2005. Later work showed the drug worked almost entirely in tumors carrying EGFR mutations, and the FDA reinstated it in 2015 for that group.

Then

The drug nearly left the market while the biomarker question was unresolved.

Now

Mutation testing became standard, and the episode became the model for biomarker-defined cancer treatment.

Why this matters now

It is the clearest precedent for what a post hoc biomarker subgroup can become, and for how many years the confirmation takes.

Sources

(7)